Margetuximab Expanded Access Program
An Expanded Access Program Providing Margetuximab in the Treatment of HER2+ Metastatic Breast Cancer in Single, Individually-approved Patients
Sponsor: TerSera Therapeutics LLC
Listed as NCT03133988, this observational or N/A phase trial focuses on HER2-positive Breast Cancer and HER2-positive Carcinoma and remains ongoing. Sponsored by TerSera Therapeutics LLC, it has been updated 13 times since 2026, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
13 versions recorded-
Mar 2025 — Present [monthly]
Approved For Marketing
-
Sep 2024 — Mar 2025 [monthly]
Approved For Marketing
-
Jul 2024 — Sep 2024 [monthly]
Approved For Marketing
-
Mar 2022 — Jul 2024 [monthly]
Approved For Marketing
-
Jan 2021 — Mar 2022 [monthly]
Approved For Marketing
Status: Available → Approved For Marketing
▶ Show 8 earlier versions
-
Jun 2020 — Jan 2021 [monthly]
Available
Status: Temporarily Not Available → Available
-
May 2019 — Jun 2020 [monthly]
Temporarily Not Available
-
Feb 2019 — May 2019 [monthly]
Temporarily Not Available
Status: Available → Temporarily Not Available
-
Sep 2018 — Feb 2019 [monthly]
Available
-
Jun 2018 — Sep 2018 [monthly]
Available
-
Apr 2018 — Jun 2018 [monthly]
Available
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Available NA
-
May 2017 — Aug 2017 [monthly]
Available NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- TerSera Therapeutics LLC
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.